675 related articles for article (PubMed ID: 23624358)
1. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
Li J; Wang Y; Zhu Y; Oupický D
J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.
Eljack S; David S; Faggad A; Chourpa I; Allard-Vannier E
Int J Pharm X; 2022 Dec; 4():100126. PubMed ID: 36147518
[TBL] [Abstract][Full Text] [Related]
3. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
4. Carbon nanotubes for delivery of small molecule drugs.
Wong BS; Yoong SL; Jagusiak A; Panczyk T; Ho HK; Ang WH; Pastorin G
Adv Drug Deliv Rev; 2013 Dec; 65(15):1964-2015. PubMed ID: 23954402
[TBL] [Abstract][Full Text] [Related]
5. Trojan horse at cellular level for tumor gene therapies.
Collet G; Grillon C; Nadim M; Kieda C
Gene; 2013 Aug; 525(2):208-16. PubMed ID: 23542073
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.
Vaughan HJ; Green JJ; Tzeng SY
Adv Mater; 2020 Apr; 32(13):e1901081. PubMed ID: 31222852
[TBL] [Abstract][Full Text] [Related]
7. Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs.
Li J; Wang Y; Xue S; Sun J; Zhang W; Hu P; Ji L; Mao Z
Int J Nanomedicine; 2016; 11():4609-4624. PubMed ID: 27695321
[TBL] [Abstract][Full Text] [Related]
8. Bioresponsive functional nanogels as an emerging platform for cancer therapy.
Huang D; Qian H; Qiao H; Chen W; Feijen J; Zhong Z
Expert Opin Drug Deliv; 2018 Jul; 15(7):703-716. PubMed ID: 29976103
[TBL] [Abstract][Full Text] [Related]
9. Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery To Potentiate the Antitumor Efficacy.
Li T; Shen X; Geng Y; Chen Z; Li L; Li S; Yang H; Wu C; Zeng H; Liu Y
ACS Appl Mater Interfaces; 2016 Jun; 8(22):13748-58. PubMed ID: 27191965
[TBL] [Abstract][Full Text] [Related]
10. Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics.
Shen X; Li T; Chen Z; Geng Y; Xie X; Li S; Yang H; Wu C; Liu Y
Int J Nanomedicine; 2017; 12():4299-4322. PubMed ID: 28652734
[TBL] [Abstract][Full Text] [Related]
11. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in drug delivery systems for targeting cancer stem cells.
Duan H; Liu Y; Gao Z; Huang W
Acta Pharm Sin B; 2021 Jan; 11(1):55-70. PubMed ID: 33532180
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.
Zoulikha M; Xiao Q; Boafo GF; Sallam MA; Chen Z; He W
Acta Pharm Sin B; 2022 Feb; 12(2):600-620. PubMed ID: 34401226
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells,
Pishavar E; Ramezani M; Hashemi M
Drug Dev Ind Pharm; 2019 Dec; 45(12):1931-1939. PubMed ID: 31609130
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
18. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid for anticancer drug and nucleic acid delivery.
Dosio F; Arpicco S; Stella B; Fattal E
Adv Drug Deliv Rev; 2016 Feb; 97():204-36. PubMed ID: 26592477
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
